Suggested remit: To appraise the clinical and cost effectiveness of baxdrostat within its marketing authorisation for treating uncontrolled or resistant hypertension.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6623
Provisional Schedule
- Committee meeting:
- 04 November 2026
- Expected publication:
- 14 April 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- AstraZeneca (baxdrostat)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Kidney Care UK
- Kidney Research UK
- National Kidney Federation
- Professional groups
- British and Irish Association of Stroke Physicians
- British and Irish Hypertension Society
- Primary Care Cardiovascular Society
- UK Kidney Association
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- None
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 April 2026 | Invitation to participate |
| 12 January 2026 - 09 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 12 January 2026 | In progress. Scoping commenced. |
| 02 September 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual